Peptides for immunity. What peptides support the immune system?
Peptides described in the context of immunity constitute an extremely heterogeneous group - from a molecule registered as a drug in several dozen countries to a peptide fragment without any approval.
Peptides described in the context of immunity constitute an extremely heterogeneous group – from a molecule registered as a drug in several dozen countries to a peptide fragment without any approval. But let’s start with a remark that sorts out the rest: “immune boosting” is not a claim that can be verified. The immune system does not have an intensity knob, and substances affecting it are called immunomodulatory, not immune-boosting – because the direction of their action depends on the context.
The article describes the mechanisms and state of evidence for five peptides and organizes their legal status. It does not contain doses or patterns of use.
All substances discussed in the article are of a research nature and are not intended for use in humans or animals. The description of their effects is based on the scientific literature – including laboratory studies, animal models and, where they exist, clinical trials conducted for registered forms of these molecules.
Why “immune boosting” is an empty claim
The immune response is not a scalar quantity. It consists of innate and adaptive immunity, the cellular and humoral arms, and excitatory and inhibitory mechanisms that must be in balance. Excessive activation is not a desirable state – it is the basis of autoimmune diseases and hypersensitivity reactions.
That’s why the literature talks about immunomodulation: shifting the balance in a specific direction, in a specific clinical context. The claim “this peptide boosts immunity” has no direction, no context, and no endpoint – and therefore can neither be confirmed nor disproved.
Five peptides, three different regulatory statuses
| Peptide | Mechanism | Status | WADA |
|---|---|---|---|
| Thymosin α-1 | T cell maturation, innate signaling | drug in approx. countries (not EU or US) | not mentioned |
| TB-500 | thymosin β-4 fragment, actin regulation | not approved – reagent research | S2 |
| BPC-157 | angiogenesis, VEGF-related pathways | not approved – research reagent | S0 |
| GHK-Cu | matrix remodeling, action anti-inflammatory | cosmetic ingredient or reagent – depending on form | not mentioned by name |
| Thymulin | zinc-dependent thymic peptide | not approved | not mentioned by name |
Thymosin α-1 – best documented, most legally complex
Mechanism
Thymosin α-1 (Tα1) is a peptide of thymic origin, described as participating in T cell maturation and innate immune signaling. Its pharmacological characteristics are presented in a review (Ancell et al., 2001, PMID 11381492), and current works also discuss it in the context of aging-related processes (Simonova et al., 2025, PMID 41373628). Its effect on macrophage polarization in oncological models has also been described (Liu et al., 2024, PMID 39357524).
State of evidence
Tα1 stands out from the rest of the peptides in this list due to the volume of clinical data. The 2024 review includes studies involving over 11,000 people in over 30 clinical trials, regarding, among others, COVID-19, autoimmune diseases and oncology (Dinetz and Lee, 2024, PMID 38308608).
There are two cautions you should take when reading this source. First, it is a narrative review, not a systematic review with a meta-analysis — and the two are methodologically different. Secondly, the authors formulate their conclusions directly in opposition to the regulatory decision of the US regulator, which makes the study a position in the dispute rather than a neutral summary.
Regulatory status – precision is needed
Tα1’s situation is unusual and often described inaccurately in both directions.
- It is a registered medicinal product in approximately 35 countries — under the international name Thymalfazine and trade name Zadaxin — for indications including hepatitis B and C and selected immunodeficiencies. It is most widely used in Asia.
- It is not authorized by the European Medicines Agency or the American FDA. This means that in the European Union, and therefore also in Poland, it is not a registered drug.
- In the United States, in 2023, the regulatory authority placed Tα1 – along with a group of other peptides – with restrictions on the preparation preparations in pharmacies.
Practical consequence: the sentence “thymosin α-1 is a registered drug” is true for parts of the world and false for Poland. Both versions are in circulation and both are used selectively.
Thymosin β-4 and TB-500 – two different things
We discuss this distinction in more detail in the material about BPC-157 and TB-500 in the context of regeneration, but we repeat it here because in the lists of “peptides for immunity” it is sometimes omitted.
Human thymosin β-4 is a peptide composed of 43 amino acid residues. Preparations sold as TB-500 contain N-terminally acetylated fragment 17-23 of this molecule with the sequence Ac-LKKTETQ – a seven-amino acid peptide, as demonstrated by liquid chromatography coupled with high resolution mass spectrometry (Esposito et al., 2012, PMID 22962027).
The function of thymosin β-4 is primarily related to actin cytoskeleton — sequestering monomeric actin and thus cell migration. The β-thymosin family is summarized in the review (Hannappel, 2007, PMID 17468232), and the repair thread is described in a study published in Nature (Bock-Marquette et al., 2004, PMID 15565145) and in a more recent review (Bock-Marquette et al., 2023, PMID 36709593).
The relationship with immunity is indirect – it concerns cell migration and repair processes, not direct modulation of the immune response. Attributing an immunostimulatory effect to TB-500 goes beyond what the data show, especially since the data concerns the full molecule, not its seven-amino acid fragment.
BPC-157
BPC-157 is a synthetic pentadecapeptide with extensive preclinical literature on tissue healing, angiogenesis, and related pathways. VEGF (Seiwerth et al., 2018, PMID 29998800). A systematic review from 2025 summarizes the state of the evidence clearly: despite two decades of preclinical publications , there is a lack of randomized clinical trials (Vasireddi et al., 2025, PMID 40756949).
The relationship with immunity is – similarly to TB-500 – indirect and results from the modulation of inflammatory and repair processes, not from a direct effect on immune system cells.
GHK-Cu
Copper tripeptide described in the context of extracellular matrix remodeling, gene expression and anti-inflammatory effects (Pickart and Margolina, 2018, PMID 29986520). It requires the same caution as the previous two: the anti-inflammatory effect is not the same as stimulating immunity – it is even the opposite. The same caveat applies to the KPV tripeptide, which we discuss separately.
The distinction between the cosmetic and research forms of this peptide is discussed in the material about peptides in cosmetics.
Tymulin – least data
Tymulin is a thymic peptide whose activity depends on the presence of zinc. Historically, it has been studied in the context of T cell maturation, and its role has been discussed in studies on thymic hormones (Bach, 1979, PMID 233313). Compared to the other peptides from this list , the literature on thymulin is clearly poorer, and there are no clinical studies assessing its use in humans. It is not approved for marketing in any form.
What the data do not show
- Does not show a preventive effect in healthy people. Clinical studies, where they exist, were conducted in diagnosed populations – not in healthy people wanting to “boost immunity” before the infectious season.
- Do not justify use in autoimmune diseases out of surveillance. Modulation of the immune response in autoimmune disease is a procedure that requires diagnosis and management by a physician.
- Does not show a safety profile for TB-500, BPC-157 or thymulin in humans – studies to determine this have not been performed.
- Does not transfer between forms. The full thymosin β-4 data do not describe the seven-amino acid fragment; data for Tα1 as a drug do not describe research material with this name.
Status and anti-doping note
Apart from thymosin α-1 – registered as a drug outside the European Union – the remaining peptides in question are not authorized for marketing as medicinal products, dietary supplements or foodstuffs.
Two of them are on the WADA Prohibited List, in different categories and prohibited at any time:
- BPC-157 – category S0 (unapproved substances), mentioned by name on the list effective from 2022.
- TB-500 and thymosin β-4 — category S2 (peptide hormones, growth factors, related substances and mimetics). Methods for detecting TB-500 in biological material have been developed and described in the analytical literature (Ho et al., 2012, PMID 23084823).
There is no path for obtaining a therapeutic use exemption for any of them because they are not registered medicines. In Poland, the Prohibited List is in force through the Polish Anti-Doping Agency (POLADA) and also covers amateur competitors taking part in competitions covered by these regulations. The broader context of approved and unapproved peptide therapies is discussed in the 2026 review (Mendias and Awan, 2026, PMID 41966639).
Frequently asked questions
Do peptides boost immunity?
The formulation itself is imprecise. The literature talks about immunomodulation – shifting the balance of the immune response in a specific direction and context. Overactivation of the immune system is not a desirable state.
Is Thymosin α-1 a drug?
Depends on jurisdiction. It is a registered medicinal product in approximately 35 countries for indications including hepatitis B and C and selected immunodeficiencies. However, it is not authorized by the European Medicines Agency or the FDA, and therefore it is not a registered drug in Poland.
Is TB-500 thymosin β-4?
Not in the full sense. Thymosin β-4 is a peptide with 43 amino acid residues, and in the TB-500 preparations, its N-terminally acetylated fragment 17-23 with the sequence Ac-LKKTETQ (PMID 22962027) was identified.
Do these peptides help in autoimmune diseases?
Autoimmune diseases require diagnosis and treatment conducted by doctor. Research on Tα1 in this area was conducted in clinical conditions, in diagnosed people – it is not a basis for independent use.
Why does the article not provide doses?
Because there is no established dosage for most of the peptides discussed – its determination is the result of the registration process, which these compounds have not undergone in the European Union.
Summary
Immune-related peptides do not form a homogeneous group either in terms of mechanism or regulatory status. Thymosin α-1 is distinguished by the volume of clinical data – the review covers over 11,000 people in over 30 trials – and an unusual regulatory situation: it is a registered drug in about 35 countries, but it is not authorized by EMA or FDA, so it is not a drug in Poland. TB-500 requires identity correction: it is not the full 43-residue thymosin β-4, but its seven-amino acid fragment Ac-LKKTETQ, and its connection with immunity remains indirect, through cell migration and repair processes. The relationship between BPC-157 and GHK-Cu is similarly indirect, with the anti-inflammatory effect being opposite to the stimulation of immunity. Tymulina has the poorest literature of the entire group. One distinction remains overriding: these substances are described as immunomodulatory, not immune-strengthening – because the direction of their action depends on the context, which no summary can replace.
Product documentation
Research material cards along with analytical documentation of the batch are available in the store’s offer. Materials intended for research use only.
The principles of handling lyophilised material, including solution preparation and solvent selection, are discussed in our guide to bacteriostatic water for peptide reconstitution.
Bibliography
- Dinetz E, Lee E. Comprehensive Review of the Safety and Efficacy of Thymosin Alpha 1 in Human Clinical Trials. Altern Ther Health Med. 2024;30(1):6-12. PMID: 38308608
- Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-885. PMID: 11381492
- Simonova MA, Ivanov I, Shoshina NS, et al. Aging and Thymosin Alpha-1. Int J Mol Sci. 2025;26(23):11470. PMID: 41373628
- Liu K, Kong L, Cui H, et al. Thymosin alpha1 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy. Cell Rep Med. 2024;5(10):101751. PMID: 39357524
- Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500. Drug Test Anal. 2012;4(9):733-738. PMID: 22962027
- Hannappel E. beta-Thymosins. Ann N Y Acad Sci. 2007;1112:21-37. PMID: 17468232
- Bock-Marquette I, Saxena A, White MD, Dimaio JM, Srivastava D. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. PMID: 15565145
- Bock-Marquette I, Maar K, Maar S, et al. Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies. Int Immunopharmacol. 2023;116:109741. PMID: 36709593
- Ho EN, Kwok WH, Lau MY, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta(4), in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012;1265:57-69. PMID: 23084823
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025;21(4):485-495. PMID: 40756949
- Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Curr Pharm Des. 2018;24(18):1972-1989. PMID: 29998800
- Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. PMID: 29986520
- Bach JF. Thymic hormones. J Immunopharmacol. 1979;1(3):277-310. PMID: 233313
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. PMID: 41966639